Navigation Links
TPI to Host Second Quarter of Fiscal Year 2013 Earnings Conference Call on Thursday, February 14, 2013 at 8:30 a.m. ET
Date:1/31/2013

CHENGDU, China, Jan. 31, 2013 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the second quarter of fiscal year 2013 ending December 31, 2012 to be held at 8:30 a.m. ET on Thursday, February 14, 2013.

Interested parties may access the call by dialing Toll free:

1-877-941-2068International: 

1-480-629-9712The conference ID is 4594892. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling

Toll free:

1-877-870-5176International: 

1-858-384-5517 From: 

02/14/13 @ 11:30 am ETTo:02/28/13 @ 11:59 pm ETReplay Pin Number:  

4594892This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://public.viavid.com/index.php?id=103373

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list (EDL) of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com , or email: ir@tpi.asia

 Tel:
+86-28-8551-6696 (Chengdu, China)
+86-134-3655-0011 (China)

Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
2. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
3. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
4. The Female Health Company Reports Second Quarter Operating Results
5. Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT
6. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
7. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
8. Elsevier Launches Second Annual Mosbys Superheroes of Nursing Contest During Nurses Week 2012
9. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
10. HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs Second Generation HIV Vaccine
11. Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... -- According to the 2016 report, a ... blood pressure monitoring system market growth. With aging, the ... respond to different pressure rates, leading to hypertension or ... cardiovascular disorders such as heart failure, stroke, coronary artery ... in prevalence each year. WHO estimates that 17 million ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
(Date:5/27/2016)... TEL-AVIV, Israel , May 27, 2016 /PRNewswire/ ... KTOV), an innovative biopharmaceutical company focused on late-stage ... by Dexcel Pharma of pivotal batches ... Food and Drug Administration (FDA). This follows Kitov,s ... pivotal Phase III trial successfully met its primary ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the maker ... been recognized as one of the best small businesses for new dads by Fatherly, ... nine small businesses providing progressive benefits to new parents on the organization’s 2016 ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses ... time to shed lights on the variety of topics detailing why we appreciate nurses ... tackles why this career has gone from being in a major recession to one ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... needing intervention to walk, the demand for a sustainable product to aid in the ... void and aid in the recovery of individuals with hemiplegia due to stroke. , ...
(Date:5/27/2016)... ... ... This campaign aims to provide a path to improved education and awareness ... change. , As nearly 795,000 Americans suffering from a new or recurrent stoke each ... an estimated 129,000 of these people dying from stroke, it’s become our nation’s fifth-leading ...
Breaking Medicine News(10 mins):